-

11:20:14 PM

VERU Stock News

VERU - Veru Inc

05/25/22 8:30 AM

Nasdaq : VERU

conferenceshigh short

Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate in a

RHEA-AI

neutral

05/18/22 8:30 AM

Nasdaq : VERU

managementcovid-19high short

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten as

RHEA-AI

neutral

05/17/22 8:30 AM

Nasdaq : VERU

conferenceshigh short

Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the

RHEA-AI

neutral

05/12/22 6:30 AM

Nasdaq : VERU

earningscovid-19high short

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

IDMC Unanimously Votes to Halt the Ongoing Phase 3 Trial of Sabizabulin for

RHEA-AI

neutral

05/11/22 6:30 AM

Nasdaq : VERU

clinical trialcovid-19high short

FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients

RHEA-AI

neutral

05/02/22 8:30 AM

Nasdaq : VERU

clinical trialcovid-19high short

FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that the FDA has granted the Company a pre-Emergency Use Authorization (EUA) meeting on May 10, 2022, for the positive Phase 3 COVID-19 study for sabizabulin. “We want to keep our

RHEA-AI

neutral

04/28/22 8:30 AM

Nasdaq : VERU

conferencesearningshigh short

Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on Thursday, May 12, 2022, before the market opens. Veru’s management will host a conference call that same

RHEA-AI

neutral

04/25/22 8:30 AM

Nasdaq : VERU

clinical trialcovid-19high short

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that results from the randomized placebo-controlled Phase 2 study of daily, oral sabizabulin in patients with severe COVID-19 at high risk for acute respiratory distress syndrome

RHEA-AI

neutral

04/11/22 6:30 AM

Nasdaq : VERU

clinical trialcovid-19high short

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

Sabizabulin Treatment Showed Statistically Significant

RHEA-AI

neutral

03/04/22 8:30 AM

Nasdaq : VERU

high short

Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that two abstracts were accepted for presentation at the 39 th Miami Breast

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

VERU Data

IndustryPharmaceutical Preparation Manufacturing
Websiteverupharma.com
CeoMitchell Steiner
Security nameVeru Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees339
Tags
- Consumer Non-Durables
- Household/Personal Care
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address48 NW 25th St Ste 102
StateFlorida
CityMiami
Zip33127-4442
CountryUnited States
Phone13125959123

About Veru Inc

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.